13.00Open13.18Pre Close5 Volume40 Open Interest61.00Strike Price6.50KTurnover0.00%IV-1.63%PremiumDec 20, 2024Expiry Date13.77Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.45Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
No comment yet